GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HLB Therapeutics Co Ltd (XKRX:115450) » Definitions » Gross Margin %

HLB Therapeutics Co (XKRX:115450) Gross Margin % : 12.21% (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is HLB Therapeutics Co Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. HLB Therapeutics Co's Gross Profit for the three months ended in Dec. 2023 was ₩1,914 Mil. HLB Therapeutics Co's Revenue for the three months ended in Dec. 2023 was ₩15,671 Mil. Therefore, HLB Therapeutics Co's Gross Margin % for the quarter that ended in Dec. 2023 was 12.21%.


The historical rank and industry rank for HLB Therapeutics Co's Gross Margin % or its related term are showing as below:

XKRX:115450' s Gross Margin % Range Over the Past 10 Years
Min: 9.32   Med: 15.13   Max: 26.17
Current: 13.52


During the past 13 years, the highest Gross Margin % of HLB Therapeutics Co was 26.17%. The lowest was 9.32%. And the median was 15.13%.

XKRX:115450's Gross Margin % is ranked worse than
87.18% of 741 companies
in the Biotechnology industry
Industry Median: 59.43 vs XKRX:115450: 13.52

HLB Therapeutics Co had a gross margin of 12.21% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for HLB Therapeutics Co was 8.00% per year.


HLB Therapeutics Co Gross Margin % Historical Data

The historical data trend for HLB Therapeutics Co's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLB Therapeutics Co Gross Margin % Chart

HLB Therapeutics Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.32 15.32 11.78 20.80 13.89

HLB Therapeutics Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.01 11.54 14.52 15.47 12.21

Competitive Comparison of HLB Therapeutics Co's Gross Margin %

For the Biotechnology subindustry, HLB Therapeutics Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HLB Therapeutics Co's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HLB Therapeutics Co's Gross Margin % distribution charts can be found below:

* The bar in red indicates where HLB Therapeutics Co's Gross Margin % falls into.



HLB Therapeutics Co Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

HLB Therapeutics Co's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=7466.2 / 53749.063
=(Revenue - Cost of Goods Sold) / Revenue
=(53749.063 - 46282.82) / 53749.063
=13.89 %

HLB Therapeutics Co's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=1914 / 15670.9
=(Revenue - Cost of Goods Sold) / Revenue
=(15670.9 - 13756.89) / 15670.9
=12.21 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


HLB Therapeutics Co  (XKRX:115450) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

HLB Therapeutics Co had a gross margin of 12.21% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


HLB Therapeutics Co Gross Margin % Related Terms

Thank you for viewing the detailed overview of HLB Therapeutics Co's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


HLB Therapeutics Co (XKRX:115450) Business Description

Traded in Other Exchanges
N/A
Address
22F, Parkview Tower, 6, Jeongja-Dong, Bundang-Gu, Seongnam-si, 463-863, KOR, 463-811
HLB Therapeutics Co Ltd is a bio company that pursues first-in-class and innovates new drug development. With the development and validation of new drugs for various hard-to-treat disorders, HLB Therapeutics is becoming a global biopharmaceutical company focused on alleviating patient suffering.

HLB Therapeutics Co (XKRX:115450) Headlines

No Headlines